enGene Therapeutics Inc. (ENGN): restructuring charge — enGene cuts workforce 50%, grants CEO performance options tied to detalimogene BLA and FDA approval milestones

enGene Therapeutics Inc.

Workforce reduction of ~50% approved June 14; estimated cash restructuring costs $5.7-6.4M, non-cash stock comp $4.7-5.0M.
Performance-based equity retention awards (options and RSUs) approved June 16, vesting upon FDA acceptance of detalimogene BLA (by Sep 30, 2027) and FDA approval (by Dec 31, 2028).
CEO Ronald Cooper granted 400,000 performance-based options at $1.75/share, vesting 50% per milestone.
Retention costs: up to $1.7M cash and $2.8M non-cash stock comp.
Majority of expenses expected in H2 2026.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

enGene Therapeutics Inc. announced a restructuring with charges of approximately $5.7 to $6.4 million in cash, as well as approximately $4.7 million to $5.0 million in non-cash stock-based compensation expense (approximately 50% of its workforce).

Type: restructuring
Charge: approximately $5.7 to $6.4 million in cash, as well as approximately $4.7 million to $5.0 million in non-cash stock-based compensation expense
Headcount: approximately 50% of its workforce

Exact text from the filing

equity retention awards, which will vest, if at all, upon the achievement of the Milestones, the Company now estimates that it will incur restructuring costs of approximately $5.7 to $6.4 million in cash, consisting primarily of employee severance, benefits, and other related costs, as well as approximately $4.7 million to $5.0 million in non-cash

View on SEC.gov

13 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-275815

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.